3/15/2019 6:19:28 AM
Wedbush Reiterates Karyopharm Therapeutics Inc. (KPTI) At Outperform With $6 Price Target
2/27/2019 8:10:16 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) FY19 Estimate To -3.26 From -3.77
2/27/2019 8:09:58 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) Q4 19 Estimate To -0.86 From -1.00
2/27/2019 8:09:41 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q3 19 Estimate To -0.78 From -0.93
2/27/2019 8:09:27 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) Q2 19 Estimate To -0.82 From -0.95
2/27/2019 8:09:12 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q1 19 Estimate To -0.79 From -0.90
2/25/2019 7:11:02 AM
Karyopharm Therapeutics Appoints Michael Mason As SVP, CFO And Treasurer
2/25/2019 7:04:05 AM
Wedbush Is Cutting Karyopharm Therapeutics Inc. (KPTI) FY19 Rev. Estimate To 4.6 M From 15.7 M
2/25/2019 7:03:34 AM
Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY19 Estimate To -3.77 From -3.63
2/25/2019 7:03:11 AM
Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) Q4 19 Estimate To -1.00 From -0.92
2/25/2019 7:02:22 AM
Wedbush Is Cutting Karyopharm Therapeutics Inc. (KPTI) Q3 19 Estimate To -0.93 From -0.86
2/25/2019 7:01:37 AM
Wedbush Reiterates Karyopharm Therapeutics Inc. (KPTI) At Outperform With $14 Down From $19 Price Target
12/4/2018 7:05:24 AM
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/3/2018 7:15:32 AM
Wedbush Reiterates Karyopharm Therapeutics Inc. (KPTI) At Outperform With $19 Price Target
12/1/2018 12:35:09 PM
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data For Selinexor At ASH 2018 Annual Meeting
11/9/2018 6:14:28 AM
Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY19 Rev. Estimate To 15.7 M From 17.4 M
11/9/2018 6:14:15 AM
Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY18 Rev. Estimate To 32.6 M From 34.7 M